Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.

Item
http://www.wikidata.org/entity/Q39965665
IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis.Secukinumab improves psoriasis symptoms in patients with inadequate response to cyclosporine A: A prospective study to evaluate direct switch.Secukinumab in the treatment of psoriasis: an update."Inflammatory skin march" in atopic dermatitis and psoriasis.Cardiovascular and Metabolic Diseases Comorbid with Psoriasis: Beyond the Skin.Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience.Anti-IL-23 and Anti-IL-17 Biologic Agents for the Treatment of Immune-Mediated Inflammatory Conditions.Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.Pustular psoriasis and related pustular skin diseases.Autoimmunity and autoimmune co-morbidities in psoriasis.Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.Rare diseases and costly treatments: the role of IL-1β in pustular psoriasis.Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.Secukinumab in the treatment of psoriasis: patient selection and perspectivesRecalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab
P2860

Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.

Item
http://www.wikidata.org/entity/Q39965665
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Efficacy and safety of secukin ...... el multicenter Japanese study.
@en
Efficacy and safety of secukin ...... el multicenter Japanese study.
@nl
type
label
Efficacy and safety of secukin ...... el multicenter Japanese study.
@en
Efficacy and safety of secukin ...... el multicenter Japanese study.
@nl
prefLabel
Efficacy and safety of secukin ...... el multicenter Japanese study.
@en
Efficacy and safety of secukin ...... el multicenter Japanese study.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Efficacy and safety of secukin ...... bel multicenter Japanese study
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921